There remains valuable open space in the ~$15B retinal vascular diseases market, despite the availability of approved biologics and clinical trials of new exploratory technologies Gen 1.0 • Eylea • Lucentis • Biosimilars Gen 1.5 • Eylea HD • Vabysmo Implants Gene Therapies High Immediacy High Immediacy + Incremental Durability Exploratory technology-products in clinical trials designed for: High Durability Approved mainstay biologics provide: DURABILITY EFFICACY High Immediacy/Efficacy + High Durability The poised opportunity is a single biologic with: ? Gen 2.0 ? 19